Gadong Taohy

ADENOMA HIPOFISARIO PROLACTINA PDF

Adenomas productores de prolactina (lactotropo) En ausencia de tumor hipofisario debe des- que muestra un macroadenoma hipofisario (adenoma. Manejo de pacientes con diagnóstico de adenoma hipofisario productor de prolactina. Experiencia del Hospital San José. Diana Cristina. of hyperprolactinemia is a PRL-secreting pituitary adenoma or prolactinoma. de un adenoma hipofisario productor de prolactina (PRL) o prolactinoma.

Author: Zulujar Mezim
Country: Greece
Language: English (Spanish)
Genre: Literature
Published (Last): 18 July 2012
Pages: 490
PDF File Size: 7.48 Mb
ePub File Size: 7.42 Mb
ISBN: 344-3-56534-168-4
Downloads: 13044
Price: Free* [*Free Regsitration Required]
Uploader: Moogura

Macroprolactina e incidentaloma hipofisário

El prolactinoma es el tumor hipofisiario funcionante m frecuente. Describir la experiencia hipfoisario servicio de endocrinolog del Hospital San Josde Bogoten el manejo de pacientes con prolactinoma que consultaron entre enero de y diciembre de Se describieron variables demogricas, clicas, seguimiento radiolico anual, prolactina PRL basal, a los 6 y 24 meses.

La mediana de duraci del tratamiento en pacientes con microprolactinomas fue 73,4 meses con una mediana de dosis acumulada adeno,a cabergolina CAB de 52 mg. En las personas con macroprolactinoma fue de 65 meses, con mediana de dosis acumulada de CAB de mg. Ocho pacientes cumplieron criterios de remisi.

There was a problem providing the content you requested

La poblaci atendida en el Hospital San Jostiene caracterticas similares a las registradas en la literatura; sin embargo, el porcentaje de remisi es bajo, lo cual, posiblemente estasociado al uso de bajas dosis de agonistas de dopamina. Se requieren estudios prospectivos para aclarar si la dosis acumulada es un factor predictor para aumentar el porcentaje de pacientes con retiro exitoso y establecer la mejor estrategia para retiro de agonistas de dopamina en pacientes con prolactinomas.

  MANTELTARIFVERTRAG DRUCKINDUSTRIE PDF

To describe our experience in the Endocrinology Service of Hospital Prolactinw Josin the treatment of patients prolaxtina prolactinoma who were seen between and Demographic and clinical variables were described, as well as radiological monitoring once yearly and basal prolactin PRL measurements at 6 and 24 months.

The patients included suffered from pituitary adenoma documented by contrast magnetic resonance imaging cMRIwith serum PRL ?

The median treatment duration for patients with microprolactinomas was For macroprolactinomas, the median treatment duration was 65 months and the median accumulated dose of cabergoline was mg.

Eight patients met remission criteria. However, the remission rate is low, possibly explained by the use of low doses of dopamine agonists.

Prospective studies are required to clarify whether the cumulative dose is a predictive factor for increasing the rate of patients with successful with- drawal and to establish the best strategy to withdraw dopamine agonists in patients with prolactinomas. Diagnosis and treatment of prolactona J Clin Endocrinol Metab ;96 2: Acta Medica Colombiana [6], N Engl J Med ; ; Surgical outcomes in hyporesponsive prolactinomas: Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: Pituitary Mar;15 1: Prolactinomas resistant to standard doses of cabergoline: Eur J Endocrinol ; 5: J Neurosurg May; 5: Endocrinol Nutr ;56 7: Cabergoline and the risk of valvular lesions in endocrine disease.

  ESPEJOS DEL TIEMPO BRIAN WEISS PDF

Eur J Endocrinol ; 1: Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol Oxf ;67 3: Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Hipotisario Metab ;93 9: Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.

Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract Dec;62 Iglesias P, Diez JJ. QJM Jun; 6: Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.

Acta Neurochir Wien ; 7: Manejo de pacientes con diagntico de adenoma hipofisario productor de prolactina. Experiencia del Hospital San Jos.